Could a weekly pill prevent TB in kids with HIV?
NCT ID NCT05122767
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a once-weekly combination of two drugs (rifapentine and isoniazid) can safely prevent tuberculosis in children and teens with HIV who are already taking the antiretroviral dolutegravir. About 92 participants aged 3 months to 17 years will receive the TB prevention for 12 weeks. Researchers will check for drug interactions and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rifapentine and isoniazid (3HP) plus dolutegravir
What this could lead to
If successful, this could provide a safe, short-course option to prevent tuberculosis in children with HIV who are on modern antiretroviral therapy.
What could go wrong
This is an early-phase (1/2) trial with only 92 participants, so results may not apply broadly. Drug interactions or side effects could still arise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital
Klerksdorp, North West, 2571, South Africa
-
The Aurum Institute: Pretoria Clinical Research Centre
Pretoria, Gauteng, 0087, South Africa